Overexpression of PDGFRβ and SC79 alone significantly promotes the in vivo growth of TNBC cells and this promotion can inhibit the anti-tumor proliferative effect of Ezetimibe in TNBC mice, whereas the addition of MK2206 can counteract the inhibitory effect of PDGFRβ overexpression on the therapeutic efficacy of Ezetimibe. The gene discussed is PDGFRB; the disease is neoplasm.